Literature DB >> 19838148

Polymer coatings and delayed arterial healing following drug-eluting stent implantation.

R A Byrne1, M Joner, A Kastrati.   

Abstract

The antirestenotic efficacy of drug-eluting stent (DES) technology is based on the local delivery and modulated release of cytotoxic drugs targeted at inhibition of neointimal hyperplasia. Control of drug-release kinetics is a critical component of device efficacy. To date this has been most effectively performed by stent coatings comprised of non-erodable (permanent) polymer which facilitate drug loading and delay elution of the active drug. In fact all 4 of the systems currently approved by the Food and Drug Administration (FDA) use a permanent polymer-based drug release system. Balancing the need for lipophilicity (to bind active drug) with hydrophilicity (which offers superior biocompatibility) is a key challenge in polymer technology. Delayed arterial healing (DAH) following DES implantation has been demonstrated in human autopsy studies and animal models and is implicated in late thrombotic occlusion and delayed loss of antirestenotic efficacy. It is characterised by 1) persistent fibrin deposition; 2) delayed endothelialization; 3) chronic inflammation; and 4) persistent platelet activation. Within segment heterogeneity in degree of healing is typical. Inflammatory response to polymer residue plays an important role and may be non-specific (monocyte-macrophage predominant) or hypersensitivity related. Failure of early preclinical models to sufficiently predict DAH in man was an important problem. Second generation DES attempt to address the issue of DAH by using thinner stent struts, lower drug load and more biocompatible polymer. At present the focus of development is towards biodegradable polymer coatings which offer the attractive prospect of controlled drug-release without the potential for late polymer-associated adverse effects. This review highlights the role of polymer coatings in determination of DES efficacy, summarises the preclinical and clinical evidence linking polymer coatings with DAH and evaluates the promise of third generation polymer-free and biodegradable polymer DES.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19838148

Source DB:  PubMed          Journal:  Minerva Cardioangiol        ISSN: 0026-4725            Impact factor:   1.347


  33 in total

Review 1.  Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis.

Authors:  Teruo Inoue; Kevin Croce; Toshifumi Morooka; Masashi Sakuma; Koichi Node; Daniel I Simon
Journal:  JACC Cardiovasc Interv       Date:  2011-10       Impact factor: 11.195

2.  Randomized comparison of biolimus-eluting stents with biodegradable polymer versus everolimus-eluting stents with permanent polymer coatings assessed by optical coherence tomography.

Authors:  Tomohisa Tada; Adnan Kastrati; Robert A Byrne; Tibor Schuster; Rezarta Cuni; Lamin A King; Salvatore Cassese; Michael Joner; Jürgen Pache; Steffen Massberg; Albert Schömig; Julinda Mehilli
Journal:  Int J Cardiovasc Imaging       Date:  2014-01-23       Impact factor: 2.357

3.  A prospective, multicenter, post marketing surveillance study to evaluate the safety and effectiveness of the Superia-Sirolimus Eluting Coronary Stent System (SSECSS) implanted during routine clinical practice in India.

Authors:  Praveen Chandra; Tarun Kumar
Journal:  Indian Heart J       Date:  2014-12-03

4.  Enhanced drug delivery capabilities from stents coated with absorbable polymer and crystalline drug.

Authors:  Wenda C Carlyle; James B McClain; Abraham R Tzafriri; Lynn Bailey; Brett G Zani; Peter M Markham; James R L Stanley; Elazer R Edelman
Journal:  J Control Release       Date:  2012-07-16       Impact factor: 9.776

5.  Ultrathin strut biodegradable-polymer sirolimus-eluting stents: being wary or going with the flow?

Authors:  Salvatore Cassese; Anna Lena Lahmann; Michael Joner
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

6.  Reduced histologic neo in-stent restenosis after use of a paclitaxel-coated cutting balloon in porcine coronary arteries.

Authors:  Denise Traxler; Rayyan Hemetsberger; Andreas Spannbauer; Katrin Zlabinger; Alfred Gugerell; Dominika Lukovic; Ljubica Mandic; Noemi Pavo; Johannes Winkler; Mariann Gyöngyösi
Journal:  Histol Histopathol       Date:  2019-10-24       Impact factor: 2.303

7.  Four-year clinical follow-up of the first-in-man randomized comparison of a novel sirolimus eluting stent with abluminal biodegradable polymer and ultra-thin strut cobalt-chromium alloy: the INSPIRON-I trial.

Authors:  Marcos Danillo Peixoto Oliveira; Expedito E Ribeiro; Carlos M Campos; Henrique B Ribeiro; Bruno L R Faillace; Augusto C Lopes; Rodrigo B Esper; George X Meirelles; Marco A Perin; Alexandre Abizaid; Pedro A Lemos
Journal:  Cardiovasc Diagn Ther       Date:  2015-08

8.  A patient with repeated catastrophic multi-vessel coronary spasm after zotarolimus-eluting stent implantation.

Authors:  Shi Hyun Rhew; Youngkeun Ahn; Eun Ae Cho; Min Sok Kim; Su Young Jang; Ki Hong Lee; Min Goo Lee; Keun Ho Park; Doo Sun Sim; Young Joon Hong; Ju Han Kim; Myung Ho Jeong
Journal:  Korean Circ J       Date:  2013-01-31       Impact factor: 3.243

9.  Safety and efficacy of the Yukon Choice Flex sirolimus-eluting coronary stent in an all-comers population cohort.

Authors:  E Xhepa; T Tada; S Cassese; L King; I Ott; M Fusaro; A Kastrati; R A Byrne
Journal:  Indian Heart J       Date:  2014 May-Jun

10.  Comparison of the Absorbable Polymer Sirolimus-Eluting Stent (MiStent) to the Durable Polymer Everolimus-Eluting Stent (Xience) (from the DESSOLVE I/II and ISAR-TEST-4 Studies).

Authors:  Alexandra J Lansky; Adnan Kastrati; Elazer R Edelman; Helen Parise; Vivian G Ng; John Ormiston; William Wijns; Robert A Byrne
Journal:  Am J Cardiol       Date:  2015-12-07       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.